TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04027894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifamycin SV MMX
Description: 200 mg Rifamycin SV-MMX® (CB-01-11)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Rifamycin SV-MMX
Description: Placebo to Rifamycin SV-MMX® Placebo tablets correspond to active tablets with respect to size, taste, and appearance.
Study: NCT05498519

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SY-4798
Description: FGFR4 selective inhibitor
Study: NCT06240104

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiac output index monitor
Description: During the spontaneous breathing test phase, the cardiac index (CI) is continuously monitored from 15-30 minutes prior to the start of the test. Patients who have successfully completed the spontaneous breathing test and increased their CI by more than 30% and meet ordinary weaning indications can have their tracheal intubation removed.
Study: NCT06017726

Intervention type: OTHER
Intervention: treatment of insulin resistance with appropriate modality according to each patient
Description: insulin resistance will be treated with either diet alone or combined diet and appropriate pharmacological treatment with the net result of normalization of HOMA IR index
Study: NCT06317493

Intervention type: OTHER
Intervention: Stimuli
Description: Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras.

Intervention type: OTHER
Intervention: Stimuli
Description: Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras.

Intervention type: OTHER
Intervention: Stimuli
Description: Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras.

Intervention type: OTHER
Intervention: Stimuli
Description: Auditory Stimuli: Pure tone bursts with main frequencies of 500, 1000, 2000, and 4000 Hz. Each tone will be presented at 10dB above the estimated individual threshold per frequency and compared to the responses to trials without auditory stimuli. Auditory stimulus duration: 25ms, there is 200ms baseline period before each trial, and 2000 ms interstimulus interval.~Visual stimuli: an animated movie adapted for the age and controlled for luminosity levels.~Pupil data will be collected through a Tobii PRO screen-based eye-tracker that measures eye-movements and pupil dilation using the infrared light cameras.
Study: NCT05351788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle（AUC 5)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be administered as an intravenous (IV) infusion every 3 weeks on Day 1 of each 21-day cycle (75mg/m²)
Study: NCT05441176

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Scoring of the DASH is performed according to references.
Study: NCT05501340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: PD-1 inhibitor (HLX10, serplulimab) 100mg intraperitoneal infusion every two weeks after radiotherapy PD-1 inhibitor (HLX10, serplulimab) 3mg/kg intravenous infusion within one week after radiotherapy every two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molgramostim
Description: 200ug qd subcutaneous injection for 7 days

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy/Sterotactic body radiotherapy
Description: 8Gy\*3f
Study: NCT04967014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP2101
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP2101
Description: Test drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2101
Description: Reference drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RLD2101
Description: Reference drug
Study: NCT06419257

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRDS
Description: VRDS is an augmented virtual reality driving simulator.
Study: NCT06189131

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventriject
Description: Ventriject is a non-exercise method for estimating V02Max

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ventriject
Description: Ventriject is a non-exercise method for estimating V02Max
Study: NCT05719675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The general outline of the intervention is divided into three phases:~1. Dispositional alteration, where the aim will be to obtain precise information on the barriers that patients encounter in carrying out their treatment and thus focus the issues to achieve an awareness of the disease by altering some of the factors that give rise to the realization of behaviors that interfere with treatment adherence.~2. Alteration of one's own behavior, focused on the development of healthy habits that are consistent with the indications of the health team for the proper management of the disease.~3. Alteration of the behavior of others, focused on the development of skills in the participants so that they are able to modify the behavior of other people close to them through health promotion strategies.
Study: NCT06136013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: 1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: 1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
Study: NCT06681051

Intervention type: DEVICE
Intervention: OSTENIL® TENDON
Description: OSTENIL® TENDON is a CE-certified viscoelastic solution intended for peritendinous or intrasheath injection, containing 2 % sodium hyaluronate from fermentation.
Study: NCT06136013

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: 1 minute of exercise at 90% of their PPO, followed by a 1-minute rest at 40-60% of their peak power output using a cycle ergometer.
Study: NCT04878965

Intervention type: DEVICE
Group type: OTHER
Intervention: Smartwatch
Description: Smartwatch apparatus to measure strong emotions (e.g., anxiety)
Study: NCT05344586

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring stretching program with neural load
Description: Participants will perform a hamstring stretch with neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, different tension parameters will be added in the following order (the next parameter shall not be introduced until the previous one has been exhausted): ankle dorsiflexion, cervical and craniocervical flexion, and hip flexion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring stretching program without neural load
Description: Participants will perform a hamstring stretch without neural load on their dominant leg. They will stretch five days a week, carrying out two repetitions of one minute each, taking a thirty second break in between. The stretch will be performed in a standing position with their dominant leg on a surface at a mid-thigh height approximately, where their knee is not fully stretched and remains unlocked and their back is in a neutral position. Participants will be encouraged to keep a maximum stretching sensation without feeling any pain. To perform the stretch, tension will be added by flexing their hip, keeping their ankle relaxed and their spine neutral.
Study: NCT06437158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: To validated the efficacy and safety of different concentrations of Bleomycin in the sclerotherapy of lymphatic malformations for pediatric patients
Study: NCT05728372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper Cu 64-DOTA-pembrolizumab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo SBRT
Study: NCT06022003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AzaCITIDine Oral Tablet
Description: AML study treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xospata
Description: R/R FLT3-mutated AML standard treatment
Study: NCT04936815

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echocardiography
Description: Transthoracic echocardiography for the detection of congenital or acquired structural heart disease.
Study: NCT05148806

Intervention type: DIAGNOSTIC_TEST
Intervention: self-administered lateral flow assays
Description: The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.

Intervention type: DIAGNOSTIC_TEST
Intervention: self-administered lateral flow assays
Description: The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.

Intervention type: DIAGNOSTIC_TEST
Intervention: self-administered lateral flow assays
Description: The lateral flow device to be used is the Fortress COVID-19 Total Antibody Device for the detection of IgM and IgG SARS-CoV-2 against the spike protein. The device has been evaluated for use in detecting anti-S in transplant patients and found to have a sensitivity of 92% and specificity of 95%.
Study: NCT06718413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronidase plus saline
Description: Injection of study drug with saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saline
Description: injection of normal saline and no study drug
Study: NCT06722950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPEOX
Description: CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
Study: NCT05052424

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of cytokines and immun cell related markers
Description: blood samples
Study: NCT05558228

Intervention type: DEVICE
Intervention: FloPatch FP120
Description: FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.

Intervention type: DEVICE
Intervention: FloPatch FP120
Description: FloPatch FP120 is an FDA 510(k) cleared device indicated for the non-invasive assessment of blood flow in the carotid artery by medical professionals, such as physicians and nurses. FloPatch uses ultrasound and the Doppler effect to assess blood flow.
Study: NCT06189456

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLUgel A
Description: BLUgel A: Hyaluronic Acid Eye Drops 0.30%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BLUyal A
Description: BLUyal A:Hyaluronic Acid Eye Drops 0.15%
Study: NCT04916327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Antioxidant
Description: Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.
Study: NCT05725447

Intervention type: OTHER
Intervention: Validity and reliability study
Description: Face-to-face questionnaire study
Study: NCT05377138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online PEP/PrEP delivery
Description: Delivery of PEP or PrEP after online consultation and HIVST image upload.
Study: NCT06438055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chemotherapy and targeted-therapy guided by organoid drug sensitivity test
Description: This study conducts drug sensitivity tests on various clinically approved drugs. The most sensitive drug for the patient is selected for treatment. This study aims to evaluate the clinical effectiveness of treatment plans guided by organoid drug sensitivity tests.
Study: NCT04440813

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education and Training by Clinicians
Description: Training in the use of PPE and education about the risks of blood exposure.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training and Education from Traditional Healers and Clinicians
Description: Training in the use of PPE and education about the risks of blood exposure.
Study: NCT04556279

Intervention type: PROCEDURE
Intervention: adrenalectomy
Description: Surgical removal of an adrenal gland containing an aldosterone secreting adenoma.

Intervention type: DRUG
Intervention: Aldosterone Antagonist
Description: Medical treatment of primary hyperaldosteronism.
Study: NCT06446986

Intervention type: OTHER
Intervention: Single and Dual-Task Timed Up and Go Test
Description: Timed Up and Go Test will be conducted. Then, for motor-motor dual-task evaluation, the test will be repeated while the subjects carry a tray containing 4 glasses of water without spilling the water. The time required to complete each test will be recorded in seconds.

Intervention type: OTHER
Intervention: Single and Dual-Task Timed Up and Go Test
Description: Timed Up and Go Test will be conducted. Then, for motor-motor dual-task evaluation, the test will be repeated while the subjects carry a tray containing 4 glasses of water without spilling the water. The time required to complete each test will be recorded in seconds.

Intervention type: OTHER
Intervention: Single and Dual-Task Tandem Walking Test
Description: The tandem walking test will be performed. Then, for cognitive-motor dual-task tandem walking test assessment, the test will be repeated while the subject completes one of 3 different cognitive tasks. These cognitive tasks used during dual-task trials will be switched between trials in an attempt to avoid a practice effect. The time required to complete each test will be recorded in seconds.~The cognitive tasks are as follows:~1. Counting down by six or seven from a randomly presented 2-digit number~2. Counting backward the months starting from a randomly selected month~3. Spelling a five-letter word backwards

Intervention type: OTHER
Intervention: Single and Dual-Task Tandem Walking Test
Description: The tandem walking test will be performed. Then, for cognitive-motor dual-task tandem walking test assessment, the test will be repeated while the subject completes one of 3 different cognitive tasks. These cognitive tasks used during dual-task trials will be switched between trials in an attempt to avoid a practice effect. The time required to complete each test will be recorded in seconds.~The cognitive tasks are as follows:~1. Counting down by six or seven from a randomly presented 2-digit number~2. Counting backward the months starting from a randomly selected month~3. Spelling a five-letter word backwards

Intervention type: OTHER
Intervention: Simple Shoulder Test
Description: Simple Shoulder Test contains 12 items and rates pain and function in patients with shoulder problems. Each item has two options and is scored either ''1 = yes'' or ''0 = no''. The total score ranges from 0 to 12. Higher scores indicate better physical functions.

Intervention type: OTHER
Intervention: Simple Shoulder Test
Description: Simple Shoulder Test contains 12 items and rates pain and function in patients with shoulder problems. Each item has two options and is scored either ''1 = yes'' or ''0 = no''. The total score ranges from 0 to 12. Higher scores indicate better physical functions.
Study: NCT06401863

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shared Decision Making Tool
Description: EHR-integrated SDM for Patients on Oral Anticoagulants and other medications that might increase the risk of hemorrhage
Study: NCT04916327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will ingest placebo (microcrystalline cellulose) pills.
Study: NCT05275595

Intervention type: OTHER
Intervention: Medical records review
Description: Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, severity of COVID-19 and associated complications, testing methods for SARS-CoV-2 virus and duration of RT-PCR positivity, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5. In patients with nephrotic syndrome, the presence of nephrotic-range proteinuria at evaluation at onset, relapse or following non-response to immunosuppression, was considered as 'relapse'.~The Patients will be followed up until discharge, death or 4weeks after diagnosis of COVID-19, whichever was earlier, until 20 January.

Intervention type: OTHER
Intervention: Medical records review
Description: Data on clinical and laboratory findings are reviewed from medical records for details of underlying disease, associated complications, therapy received, and duration of hospital stay. Underlying CKD was categorized as nephrotic syndrome, other kidney diseases with CKD stage 1-5.
Study: NCT06267391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReCET Treatment
Description: Treatment arm will receive the ReCET therapy. The ReCET procedure utilizes the ReCET catheter to deliver non-thermal pulsed electric field to the first portion of the small intestine (duodenum) to induce cell regeneration. The catheter is introduced to the duodenum through the mouth using a guide wire and the therapy is applied to treat the duodenum. Participants will be followed for 12 months post procedure.
Study: NCT06722950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CAPEOX
Description: CAPEOX: 130mg/m2 of oxaliplatin (D1, central intravenous drip for 2h (time window + 20min)), 1000mg/m2 of capecitabine tablets each time, orally, twice a day (D1-D14, morning and evening); repeat the CAPEOX chemotherapy regimen every 3 weeks.
Study: NCT06267391

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: The Control arm will receive a sham procedure. The sham procedure consists of placing the ReCET catheter as described above without therapy applied. Participants will be followed for 12 months post procedure and will be offered cross-over to receive the ReCET therapy after 12 months.
Study: NCT05580939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: They use Web-based Simulation Application for 4 weeks
Study: NCT05579808

Intervention type: PROCEDURE
Intervention: Epidural Analgesia
Description: Using an aseptic technique while the patient is in sitting position, an epidural catheter was placed at the L2-L3 or L3-L4 interspace. Analgesia was established with the epidural administration of a low dose of local anaesthetic, plus a lipid-soluble opioid (ropivacaine 0.1% and sufentanyl 0.5%, 20 mL). Analgesia was maintained with a top-up regimen, using intermittent manual epidural boluses of increasing concentrations of ropivacaine, with up to 0.15% at full dilation, according to specific needs of individual participants.
Study: NCT05811169

Intervention type: GENETIC
Intervention: Next generation sequencing
Description: Next generation sequencing
Study: NCT05495867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant placement
Description: implant placement in edentulous area

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: implant placement
Description: implant placement in edentulous area
Study: NCT06722950

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo：3 times a day (daily), taken with boiled water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC591
Description: AC591 : 3 times a day (daily), taken with boiled water.